Could This FDA Approval Be a Boost for Merck?

Could This FDA Approval Be a Boost for Merck?

Submitted by admin on April 28, 2022 - 11:04am
Source: 
Motley Fool
News Tags: 
Merck
Keytruda
FDA
endometrial cancer
Headline: 
Could This FDA Approval Be a Boost for Merck?
snippet: 
  • Keytruda now has access to another patient pool of several thousand patients.
  • The indication could generate $200 million in annual revenue for Merck.
  • Merck looks like a stock that offers something for everyone to like.

Do Not Allow Advertisers to Use My Personal information